1. Japan Stocks

  2. •

    Basic Materials

  3. •

    Chemicals
Sumitomo Chemical Company, Limited

Sumitomo Chemical Company, Limited

4005.T
Sumitomo Chemical Company, LimitedJP flagTokyo Stock Exchange
586.80
JPY
+3.40
- -
969.05BMarket Cap
Sumitomo Chemical Company, Limited
4005.T
(Tokyo Stock Exchange)

Recent

price

586.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
1,205.68
1,191.61
1,194.46
1,372.73
1,454.14
1,286.04
1,185.83
1,339.68
1,418.06
1,361.34
1,398.77
1,691.35
1,770.84
1,496.25
1,593.17
- -
770.49
Revenue per Share
14.86
3.42
-31.25
22.62
31.93
49.84
46.81
81.81
72.17
18.91
28.16
99.16
4.27
-190.69
23.59
- -
- -
Basic EPS, GAAP
107.18
76.16
104.97
118.91
159.6
159.81
113.61
179.35
127.3
64.84
229.03
105.03
-19.55
-124.86
- -
- -
39.13
Free Cash Flow per Basic Share
9.04
12.01
9.01
6
9.01
11.01
13
17
23
22
12
19
25.98
12.01
- -
- -
5.99
Dividend per Share
358.21
351.58
311.75
326.92
347
389.31
436.16
506.75
556.66
549.02
577.52
650.82
600.23
408.54
446.65
- -
422.78
Book Value per Share
349.18
354.03
344.04
452.2
559.29
515.84
466.37
548.43
616.74
444.36
496.43
603.28
500.51
383.82
352.88
- -
359.51
Tangible Book Value per Share
1,644
1,635
1,635
1,635
1,634
1,634
1,635
1,635
1,635
1,635
1,635
1,635
1,635
1,635
1,636
1,640
1,635
Basic Weighted Avg Shares
1,982,435
1,947,884
1,952,492
2,243,794
2,376,697
2,101,764
1,939,069
2,190,509
2,318,572
2,225,804
2,286,978
2,765,321
2,895,283
2,446,893
2,606,281
- -
1,260,018
Sales/Revenue/Turnover
4.44
3.12
2.31
4.49
5.36
7.82
4.34
8.93
6.29
5.76
6.54
6.25
-0.84
-17.63
6.61
- -
-25.77
Operating Margin (%)
147,009
114,890
115,483
115,734
119,177
116,602
110,308
107,103
112,495
131,741
136,017
156,667
167,957
157,522
- -
- -
78,869
Depreciation Expense
24,434
5,587
-51,076
36,977
52,192
81,451
76,540
133,768
117,992
30,926
46,043
162,130
6,987
-311,838
38,591
- -
- -
Net Income, GAAP
46.03
34.66
427.37
36.24
39.07
28.67
10.82
26.02
19.06
58.31
50.6
25.76
20,387.88
- -
26.52
- -
- -
Effective Tax Rate (%)
1.23
0.29
-2.62
1.65
2.2
3.88
3.95
6.11
5.09
1.39
2.01
5.86
0.24
-12.74
1.48
- -
- -
Profit Margin (%)
300,148
259,369
238,790
293,313
391,061
251,720
184,648
225,868
286,089
148,578
493,779
639,151
484,517
232,395
544,387
- -
384,853
Working Capital
701,226
682,741
707,176
731,591
693,632
604,270
573,476
552,971
582,965
838,139
1,100,677
1,089,190
1,064,463
977,581
1,033,236
- -
1,048,496
LT Debt
758,886
720,901
747,482
934,506
1,118,216
1,029,079
1,115,903
1,252,214
1,351,886
1,392,592
1,482,119
1,701,977
1,489,189
1,164,366
1,074,415
- -
1,086,495
Total Equity
2.6
2.2
-8.18
3.35
3.75
5.84
3.83
6.98
5.43
2.16
2.64
4.31
161.97
- -
4.96
- -
- -
Return on Invested Capital (%)
0.82
0.19
-5.65
1.46
2.2
3.26
3.13
5.41
4.52
0.67
1.23
5.48
-281.93
- -
6.35
- -
- -
Return on Capital (%)
4.18
0.96
-9.42
7.08
9.48
13.54
11.34
17.35
13.57
3.42
5
16.15
0.68
-37.81
5.52
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
585,905
- -
445,890
LT Borrowings
977,581
- -
1,048,496
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,636
- -
1,637
Market Capitalization
553,718
563,708
666,407

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
1,675,882
- -
1,671,123
Cash, Cash Equivalents & STI
248,787
- -
323,809
Accounts Receivable, Net
620,022
- -
550,772
Inventories
709,637
- -
712,355
Total Current Liabilities
1,443,487
- -
1,286,270
Payables & Accruals
- -
- -
- -
ST Debt
585,905
- -
445,890
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
563,143
623,732
619,994
640,024
2,446,893
2025
- -
- -
- -
- -
2,606,281
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-190.69
2025
- -
- -
- -
- -
23.59
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6.01
0.02
5.99
- -
12.01
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Hubei Biocause Heilen Pharmaceutical Co., Ltd. (301211.SZ)
North Chemical Industries Co., Ltd. (002246.SZ)
Orbia Advance Corporation, S.A.B. de C.V. (MXCHF)
Braskem S.A. (BRKM6.SA)
Primo Chemicals Ltd. (PRIMO.NS)
Zaklady Azotowe Pulawy S.A. (ZAP.WA)
Business
Sumitomo Chemical Company, Limited (4005.T) manufactures and markets a broad portfolio of chemicals and related products through five principal segments: Agro & Life Solutions; ICT & Mobility Solutions; Advanced Medical Solutions; Essential & Green Materials; and Sumitomo Pharma. The Agro & Life Solutions segment provides crop protection chemicals including pesticides and insecticides, fertilizers, agricultural materials, household insecticides, products for infectious disease control, and feed additives; the ICT & Mobility Solutions segment offers optical products, color filters, semiconductor processing materials, compound semiconductor materials, touch screen sensor panels, and battery components; the Advanced Medical Solutions segment develops ethical pharmaceuticals, radiopharmaceuticals, and radiation therapy equipment; the Essential & Green Materials segment produces synthetic resins, raw materials for synthetic fibers, industrial chemicals, methacrylates, processed synthetic resin products, aluminum and alumina, synthetic rubber, engineering plastics, dyes, additives, and battery parts; and Sumitomo Pharma focuses on pharmaceuticals including regenerative medicine initiatives. The company, founded in 1913 and headquartered in Tokyo, Japan, maintains global operations with manufacturing facilities, R&D centers, and sales networks across Asia, North America, Europe, Latin America, and other regions, serving industries such as agriculture, healthcare, electronics, energy, and automotive. Recent strategic developments include the November 2025 agreement to acquire 100% of Asia Union Electronic Chemical Corporation, a Taiwanese semiconductor process chemicals firm, to bolster its global manufacturing footprint with new bases in Taiwan and the United States; the February 2025 acquisition of the LCP neat resin business intangible asset from Syensqo SA/NV to expand product and technology offerings; the full acquisition of Philagro Holding S.A. in France and Kenogard S.A. in Spain and Portugal to strengthen European crop protection sales; and an increase in ownership of a regenerative medicine CDMO to 66.6% effective October 2024, alongside plans for a new joint venture with Sumitomo Pharma.